ACAD
30.24
-2.76
-8.36%
AEMD
5.21
+0.05
+0.97%
APRI
0.499
+0.003
+0.6865%
ARNA
1.665
-0.045
-2.632%
ATEC
0.235
+0.01
+4.2667%
CNAT
2.73
+0.01
+0.37%
CRXM
0.19
0.00
0.00%
CYTX
0.272
-0.028
-9.303%
DXCM
62.185
-2.915
-4.478%
GNMK
5.65
-0.19
-3.25%
HALO
10.38
-0.47
-4.33%
ILMN
132.39
-3.53
-2.60%
INNV
0.086
0.00
0.00%
INO
10.51
-0.37
-3.40%
ISCO
3.88
+0.16
+4.30%
ISIS
57.56
0.00
0.00%
LGND
120.65
-2.37
-1.93%
LPTN
0.235
+0.02
+9.302%
MBVX
0.66
0.00
0.00%
MEIP
1.41
-0.03
-2.08%
MNOV
6.87
-0.13
-1.86%
MRTX
20.95
-0.6
-2.78%
MSTX
0.29
+0.00
+0.1034%
NBIX
45.4
-1.31
-2.80%
NUVA
51.94
-0.67
-1.27%
ONCS
1.82
-0.06
-3.19%
ONVO
2.715
-0.115
-4.064%
OREX
0.468
+0.001
+0.214%
OTIC
13.84
-0.12
-0.86%
QDEL
16.73
-0.45
-2.62%
RCPT
231.96
0.00
0.00%
RGLS
5.52
-0.41
-6.91%
RMD
55.74
-0.39
-0.69%
SPHS
1.37
+0.03
+2.24%
SRNE
7.03
+0.05
+0.72%
TROV
3.798
-0.192
-4.812%
VICL
0.38
0.00
-0.1052%
VOLC
18
0.00
0.00%
ZGNX
10.28
-0.05
-0.48%
ACAD
30.24
-2.76
-8.36%
AEMD
5.21
+0.05
+0.97%
APRI
0.499
+0.003
+0.6865%
ARNA
1.665
-0.045
-2.632%
ATEC
0.235
+0.01
+4.2667%
CNAT
2.73
+0.01
+0.37%
CRXM
0.19
0.00
0.00%
CYTX
0.272
-0.028
-9.303%
DXCM
62.185
-2.915
-4.478%
GNMK
5.65
-0.19
-3.25%
HALO
10.38
-0.47
-4.33%
ILMN
132.39
-3.53
-2.60%
INNV
0.086
0.00
0.00%
INO
10.51
-0.37
-3.40%
ISCO
3.88
+0.16
+4.30%
ISIS
57.56
0.00
0.00%
LGND
120.65
-2.37
-1.93%
LPTN
0.235
+0.02
+9.302%
MBVX
0.66
0.00
0.00%
MEIP
1.41
-0.03
-2.08%
MNOV
6.87
-0.13
-1.86%
MRTX
20.95
-0.6
-2.78%
MSTX
0.29
+0.00
+0.1034%
NBIX
45.4
-1.31
-2.80%
NUVA
51.94
-0.67
-1.27%
ONCS
1.82
-0.06
-3.19%
ONVO
2.715
-0.115
-4.064%
OREX
0.468
+0.001
+0.214%
OTIC
13.84
-0.12
-0.86%
QDEL
16.73
-0.45
-2.62%
RCPT
231.96
0.00
0.00%
RGLS
5.52
-0.41
-6.91%
RMD
55.74
-0.39
-0.69%
SPHS
1.37
+0.03
+2.24%
SRNE
7.03
+0.05
+0.72%
TROV
3.798
-0.192
-4.812%
VICL
0.38
0.00
-0.1052%
VOLC
18
0.00
0.00%
ZGNX
10.28
-0.05
-0.48%
Home » Archive by Category

Syndication

Lab Assistant I

April 27, 2016 – 9:54 am

GENERAL SUMMARY:
The Lab Assistant I is responsible for providing support for the Medicinal Chemistry Department ensuring that assigned supplies are ordered and stocked to assist in completing daily tasks and accomplish goals. Stocking, returning, a […

Compugen First Quarter 2016 Conference Call and Webcast Scheduled for Tuesday, May 10, 2016 at 10:00 AM ET

April 27, 2016 – 4:15 am

HOLON, Israel, April 27, 2016 /PRNewswire/ — Compugen Ltd. (NASDAQ: CGEN), a leading predictive drug discovery company, today announced that the Company will host a conference call at 10:00 AM ET on Tuesday, May 10, 2016, to review the first quarter 2016 results. The quarterly results will be released on the Company’s website (www.cgen.com) prior to the conference call.

To access the conference call, please dial 1-888-407-2553 from the US, or +972-3-918-0685 internationally. The conference call and the accompanying slide presentation will also be available via webcast through Compugen’s website, located at the following link.

A replay of the conference call and the accompanying slide presentation will be available approximately two hours after the completion of the conference call. To access the replay, please dial 1-888-326-9310 from the US or +972-3-925-5925 internationally. The replay will be available through May 12, 2016.

About Compugen
Compugen is a leading therapeutic discovery company utilizing its broadly applicable predictive discovery infrastructure to identify novel drug targets and develop first-in-class biologics. The primary focus of the Company’s current pipeline is on immune checkpoint target candidates discovered by the Company, potentially providing the basis for a next wave of therapeutics for cancer immunotherapy. Compugen’s business model is based on selectively entering into collaborations for its novel target candidates and drug product candidates at various stages of research and development under revenue-sharing agreements. The Company is headquartered in Israel, with R&D facilities in Israel and South San Francisco. At the US facilities, monoclonal antibody therapeutic candidates are discovered and developed against the Company’s novel target candidates. For additional information, please visit Compugen’s corporate website at http://www.cgen.com/.

Forward-Looking Statement
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by the use of terminology such as “will,” “may,” “expects,” “anticipates,” “believes,” and “intends,” and describe opinions about future events. These forward-looking statements involve known and unknown risks and uncertainties that may cause the actual results, performance or achievements of Compugen to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Among these risks: Compugen’s business model is substantially dependent on entering into collaboration agreements with third parties and may not be successful in generating adequate revenues or commercializing aspects of our business model, and the development and commercialization of therapeutic candidates involve many inherent risks, including failure to progress to clinical trials or, if they progress to or enter clinical trials, failure to receive regulatory approval. These and other factors are more fully discussed in the “Risk Factors” section of Compugen’s most recent Annual Report on Form 20-F as filed with the Securities and Exchange Commission as well as other documents that may be subsequently filed by Compugen from time to time with the Securities and Exchange Commission. In addition, any forward-looking statements represent Compugen’s views only as of the date of this release and should not be relied upon as representing its views as of any subsequent date. Compugen does not assume any obligation to update any forward-looking statements unless required by law.

Company contact:
Tsipi Haitovsky
Global Media Liaison
Compugen Ltd.
Email: tsipih@cgen.com
Tel: +972-52-598-9892

SOURCE Compugen Ltd.

Biocept Collaborates with MedStar Georgetown University Hospital for Liquid Biopsy Study

April 27, 2016 – 4:00 am

Study focuses on Resistance Mechanisms in Non-Small Cell Lung Cancer; Data Expected to Further Support the Clinical Utility of Biocept’s Liquid Biopsy Technology

SAN DIEGO, April 27, 2016 /PRNewswire/ — Biocept, Inc. (NASDAQ: BIOC), a leading molecular diagnostics company with a commercial liquid biopsy technology focused on cancer treatment and monitoring, announces the initiation of a collaborative study with MedStar Georgetown University Hospital to evaluate resistance biomarkers in patients diagnosed with non-small cell lung cancer (NSCLC) who are currently being treated with EGFR inhibitors or chemotherapy.  Tumors from patients with advanced NSCLC are routinely screened for the presence of EGFR mutations, with these mutations occurring in approximately 10 to 20 percent of NSCLC patients.

The study is being conducted at the Georgetown Lombardi Comprehensive Cancer Center under the direction of Giuseppe Giaccone, MD, PhD, Associate Director for Clinical Research for the MedStar Health Cancer Network’s Washington Region and an internationally recognized expert in the field of lung cancer and developmental therapeutics. Biocept will monitor various clinically validated biomarkers in patients with lung cancer, including EGFR, MET, ALK and BRAF, using its proprietary circulating tumor cell (CTC) and cell free circulating tumor DNA (ctDNA) dual platform technology. Data from the study is expected to further build and strengthen the clinical utility for Biocept’s blood-based biomarker testing platforms.

“Studying various forms of resistance mechanisms allows us to further expand upon and develop evidence supporting the utility of clinically actionable personalized treatment information for patients with metastatic lung cancer,” said Veena Singh, MD, Biocept’s Senior Vice President and Senior Medical Director. “Treatment with currently approved targeted TKI therapies have known benefits for patients with various EGFR activating mutations; however, nearly all of these patients will eventually develop resistance to their therapies, which results in disease progression.

“Our study is focusing on identifying active evolving resistance mechanisms through blood-based testing in order to monitor the mutations in the tumor and importantly identify real-time treatment options for these patients,” added Dr. Singh.  “We are delighted to be collaborating on this study with highly respected Dr. Giaccone and a top-tier institution such as MedStar Georgetown.”

“Current standard of care is to use tumor biopsies by invasive surgical techniques or interventional radiology to both re-stratify patients with NSCLC when signs of progression are identified and to monitor these patients for key mechanisms of resistance,” said Dr. Giaccone. “These biopsies have a quantifiable rate of complications and risk.  The ability to identify resistance mechanisms through blood-based liquid biopsy monitoring allows for detection and analysis without the need to obtain more tissue.”

About MedStar Georgetown University Hospital and the Georgetown Lombardi Comprehensive Cancer Center
The Georgetown Lombardi Comprehensive Cancer Center is part of Georgetown University Medical Center and MedStar Georgetown University Hospital.  It is a state-of-the-art cancer center housing more than 240,000 square feet of clinic and research space.  Georgetown Lombardi is a National Cancer Institute (NCI)-designated Comprehensive Cancer Center.  MedStar Georgetown University Hospital is a not-for-profit, acute-care teaching and research hospital located in Northwest Washington, D.C. and is a part of the greater MedStar network, the largest healthcare provider in Maryland and the Washington, D.C., region.

About Biocept
Biocept, Inc. is a molecular diagnostics company with commercial tests targeting lung, breast, gastric, colorectal and prostate cancers and melanoma.  The company uses its proprietary liquid biopsy technology to provide physicians with more precise information for treating and monitoring patients with cancer.  The company’s patented Target Selector™ liquid biopsy technology platform captures and analyzes circulating tumor DNA in both circulating tumor cells (CTCs) and in plasma (ctDNA).  After thousands of tests, the platform has proven to be effective in identifying cancer mutations.  Biocept plans to introduce additional CLIA-validated tests in the near term.  For additional information, please visit www.biocept.com.

Forward-Looking Statements Disclaimer Statement
This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like “may,” “will,” “should,” “could,” “expect,” “anticipate,” “estimate,” “believe,” “intend,” or “project” or the negative of these words or other variations on these words or comparable terminology. To the extent that statements in this release are not strictly historical, including without limitation statements as to the expected results of the study, our ability to improve the detection and treatment of cancer, our impact on diagnostic strategies, our ability to enhance individual cancer treatments and planned future offerings, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous risk factors as set forth in our Securities and Exchange Commission (SEC) filings. The effects of such risks and uncertainties could cause actual results to differ materially from the forward-looking statements contained in this release. We do not plan to update any such forward-looking statements and expressly disclaim any duty to update the information contained in this press release except as required by law. Readers are advised to review our filings with the SEC, which can be accessed over the Internet at the SEC’s website located at www.sec.gov.

Logo – http://photos.prnewswire.com/prnh/20151013/276540LOGO

 

SOURCE Biocept, Inc.

PROCESS DEVELOPMENT ASSOCIATE – Halozyme Therapeutics, Inc. – San Diego, CA

April 26, 2016 – 5:04 pm

BS with 2-4 years / MS with 1-2 years of experience in biotechnology industry. Supports the development and execution of scalable protein purification processes…
From Halozyme Therapeutics, Inc. – 27 Apr 2016 00:04:26 GMT
– V…

Quality Control Lead – La Jolla Biologics, Inc – San Diego, CA

April 26, 2016 – 3:25 pm

Quality Control experience in GMP biopharmaceutical or biotechnology industry:. 5+ years of professional Quality Control experience in GMP biopharmaceutical or…
From Indeed – 26 Apr 2016 22:25:18 GMT
– View all San Diego jobs

Quality Control Lead (2016-018) – La Jolla Biologics, Inc – San Diego, CA

April 26, 2016 – 3:25 pm

Quality Control experience in GMP biopharmaceutical or biotechnology industry:. 5+ years of professional Quality Control experience in GMP biopharmaceutical or…
From Indeed – 26 Apr 2016 22:25:18 GMT
– View all San Diego jobs

Biotech Global Lead Generation Specialist (Sorrento Valley)

April 26, 2016 – 2:25 pm

Do you want to be part of a young, hungry team that takes a small business to the next level? Do you have the entrepreneurial spirit needed to be one of the founding members of a Sales team? Do you want your work to make a huge impact on the organiza […

Quality Control Manager (San Diego)

April 26, 2016 – 1:56 pm

ISO 9001 Certified, QSR 21 CRT 820 and ICH Q7 CRF 210 compliant Midsize Biotech Company is seeking a Quality Control Manager.
This person will be responsible for the management of an analytical laboratory that tests in-coming raw materials, in-proce […

HIRING 5 SALES REPS – Interview NOW & Start Monday May 2nd (San Diego)

April 26, 2016 – 11:02 am

15-year-old Digital Marketing company seeking to hired new inside sales consultants. The company provides Social Media, Web Marketing, SEO and other online marketing solutions to businesses throughout the USA.
We especially are seeking to hire energe […

Finistere, IFC Team Up on New Ag Fund Willow Hill Ventures

April 26, 2016 – 10:48 am

Agricultural technology startups face challenges finding the capital to scale their companies, but they also struggle to find the farmland to test their products. Two companies experienced in…

[[Click headline to continue reading.]]